Overview

Rt-PA in the Treatment of Acute Ischemic Stroke

Status:
Completed
Trial end date:
1969-12-31
Target enrollment:
Participant gender:
Summary
To collect additional confirmatory data on alteplase(rt-PA) in the European setting and to demonstrate that the treatment of patients between 3 and 4.30 hours of onset of symptoms of acute ischemic stroke with rt-PA compared to placebo-treated patients will result in an improved clinical outcome without increase of fatality rate.
Phase:
Phase 3
Details
Lead Sponsor:
Boehringer Ingelheim
Treatments:
Tissue Plasminogen Activator